This book presents a comprehensive collection of essential and up-to-date methods for studying both the biology of microtubules and the mechanisms of action of microtubule-interacting drugs. The book contains a straightforward presentation of readily reproducible protocols, tips for troubleshooting, and advice on avoiding common mistakes. Basic scientists and clinical researchers will benefit from this collection.

We anticipate the book to be a definitive text on the subject that explores all aspects of the study of adrenal cancer and the treatment of patients with the disease. Chapters will cover epidemiology, pathogenesis, genetics, cancer stem cells, historic and emerging therapies, mouse models of adrenal cancer, new developments in tumor profiling, worldwide collaborative groups and tumor registries together with resources for the practitioner and community of adrenal cancer scientists.

We do not wish this book to compete with the other larger books in the Endocrine and Endocrine Surgery literature. In addition, it is not expected to cover benign adrenal diseases that have been covered in detail in other venues. We envision this book to be a very specialized and exhaustive text on basic, translational and clinical aspects of adrenal cancer.

Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.

Developments in the understanding of the biology and treatment of Hodgkin's disease and non Hodgkin's lymphoma are moving at a rapid pace. New technologies, such as gene expression profiling in malignancy have been implemented using lymphoma to demonstrate their clinical utility. The objective of this volume is to review relevant aspects of the biology, diagnosis, and management with particular emphasis on emerging data available for this disease.

This volume contains the proceedings of the Second International Symposium on Biology of Brain Tumour. The first Symposium was held in 1979 at Gardonne Riviera, Italy. This meeting was planned in order to coincide with the lOOth Anniversary of the first reported operation for glioma in London on November 25, 1884. Since the first meeting, the field of neuro-oncology has made remarkable progress in understanding both basic and clinical factors of significance to patients with brain tumor. While the earlier meeting dealt to a large extent with clinically oriented studies, this symposium was more heavily weighted toward the biology of brain tumour and improving our understanding at the physiologic, biochemical, pharmacologic, and cellular level. The meeting was divided according to scientific content into presentations and discussions as well as posters for more leisurely viewing, so as to allow the main themes of the meeting to sequentially develop. The first session dealt extensively with neuro-oncology at the molecular level and included considerable discus sion of material related to the babic biochemical milieu in which tumors originate, proliferate, and eventually destroy the brain. Classic neuropathology has been the mainstay of tumor identification and characteriza tion, however, the process of classification has become much more complex. The availability of a variety of new tools has allowed investigation into the validity of the more traditional classification systems as well as the development of newer biologically related concepts.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general onco logy textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often prelimi nary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by divid ing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

It is now becoming very clear that the development and progression of tumor towards the malignant (metastatic) phenotype depends tightly on the interaction between the tumor cells and the tumor microenvironment. Tumor cells respond to stimuli generated within the tumor microenvironment for their growth advantage while the tumor cell themselves reshape and remodel the architecture and function of their extracellular matrices. The term tumor microenvironment is a wide umbrella consisting of stromal cells such as fibroblasts and endothelial cells and infiltration immune cells including T and B cells, macrophages, and other inflammatory cells (PMNs). These different components of the tumor microenvironment could have stimulatory and inhibitory effects on tumor progression by regulating the gene expression repertoire within the tumor cells on one hand and the stroma cells on the other. In this volume we have seven contributors who will discuss several different aspects on the cross talk within the tumor microenvironment components leading to the acquisition of the metastatic phenotype. It is our hope that these state-of-the-art studies will shed further light on our understanding of these complicated processes.

In Breast Cancer: Cellular and Molecular Biology Kluwer Academic Pub lishers, 1988], we tried to present an introduction to the emerging basic studies on steroid receptors, oncogenes, and growth factors in the regulation of normal and malignant mammary epithelium. The response to this volume was superb, indicating a tremendous interest in basic growth regulatory mechanisms governing breast cancer and controlling its malignant progres sion. In the two years since its publication, much new and exciting in formation has been published and the full interplay of regulatory mechanisms is now beginning to emerge. We have divided this book into four sections that we hope will unify important concepts and help to crystallize areas of consensus and/or disagreement among a diverse group of basic and clinical scientists working on the disease. The first section is devoted to studies on oncogenes, antioncogenes, proliferation, and tumor prognosis. The first chapter, by Sunderland and McGuire, introduces the characteristics of breast cancer as studied by patho logists to establish prognostic outcome. Of particular interest is a new proto oncogene called HER-2 (or neu), which is rapidly becoming accepted as a valuable new tumor marker of poor prognosis. The second chapter, by Lee Bookstein and Lee, introduces the best known antioncogene, the retinoblas toma antioncogene, whose expression is sometimes lost in breast cancer. Malignant progression appears to be influenced by the balance of proto oncogene and antioncogene expression."

The recent FDA approval of Provenger as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumabr, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "first-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.

Complex chemical mixtures impact our health every day. In the United States, and also in Central and Eastern Europe, there are a number of locations where complex chemical mixtures have been released to environmental media. Although exposure to mixtures is common, minimal information exists to quantify these exposures, or to determine their impact on human or ecological receptors. These proceedings present some of the most current research conducted to quantify complex mixtures in the environment and investigate their potential impact on human health. Many of the manuscripts reported in these proceedings represent the most up-to-date measurements of population exposures in Central and Eastern Europe. These studies are of value to health and environmental professionals around the world as they develop strategies for assessing exposures, remediating contaminated environments, and improving public health.

In September 1998 experts from 19 countries came together for an interdisciplinary discussion of the function of animal peroxidases, a family of enzymes embracing myeloperoxidase, eosinophil peroxidase, thyroid peroxidase and lactoperoxidase. Their papers have been updated for publication, yielding a wide-ranging overview of the state of the art. The chapters cover a wide range of topics, including three-dimensional structure of representative family members, their biosynthesis and intracellular transport, mechanism of action as well as applications to clinical medicine. They are of clinical relevance in, for example, arteriosclerosis, multiple sclerosis, infections, tumorigenesis, rheumatic diseases and hypothyroidism. This book forms an excellent introduction for anyone interested in the peroxidase family of enzymes.

Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance."

A state-of-the art collection of readily reproducible laboratory methods for assessing chemosensitivity in vitro and in vivo, and for assessing the parameters that modulate chemosensitivity in individual tumors. Chemosensitivity, Volume 1: In Vitro Assays provides a panel of 16 in vitro measures of chemosensitivity in adherent and non-adherent cells for single agents and combinations of agents. In addition to immunohistochemical and imaging approaches, these assays include clonogenic, colorimetric, fluorometric, and physiological assays. Highlights include image analysis to assess drug sensitivity, high throughput approaches using green fluorescent protein, DIMSCAN (a microcomputer fluorescence-based assay), and the ChemoFx assay used in biotechnology. A companion volume, Volume 2: In Vivo Models, Imaging, and Molecular Regulators, provides protocols for classifying tumors into response categories and customizing chemotherapy regimens to individual patients.

Malignant disease of the genitourinary tract continues to provide a major health hazard. The study of these disease processes has been hampered at the clinical level as there has been a serious lack of reasonably controlled treatment trials, and at the basic science level as many of the animal model systems do not compare favorably with the human tumor situation. This volume defines current cancer treatment and research and its appli cation to the control of human genitourinary malignancy. The authors have developed their chapters in such a way as to provide an up-to-date resource for the clinician who is involved in day-to-day patient care problems, for the clinician-investigator who is attempting to construct programs designed to evaluate the impact of current treatments, and for the clinician-scientist who is seeking to apply basic research technology and skills to understand ing and control in this disease area. This book does not attempt to cover the entire breadth of urinary malig nant disease, but focuses in depth on specific problem areas. It provides the reader with sufficient background and understanding for him to be able to evaluate future studies in the areas addressed, or even to develop his own projects. A reasonable balance has been established between clinical and basic research problems, recognizing that the two disciplines truly are not separable. The book serves to define the state of the art and, as such, will of urologic oncology."

Epigenetic modifications underlie all aspects of human physiology, including stem cell renewal, formation of cell types and tissues. They also underlie environmental impacts on human health, including aging and diseases like cancer. Consequently, cracking the epigenetic "code" is considered a key challenge in biomedical research. Chromatin structure and function are modified by protein complexes, causing genes to be turned "on" or "off" and controlling other aspects of DNA function. Yet while there has been explosive growth in the epigenetics field, human chromatin-modifying machines have only recently started to be characterized. To meet this challenge, our book explores complementary experimental tracks, pursued by expert international research groups, aimed at the physical and functional characterization of the diverse repertoire of chromatin protein machines - namely, the "readers, writers and erasers" of epigenomic marks. These studies include the identification of RNA molecules and drugs that interact selectively with components of the chromatin machinery. What makes this book distinctive is its emphasis on the systematic exploration of chromatin protein complexes in the context of human development and disease networks.

This thesis presents the development of theranostic gold nanostars (GNS) for multimodality cancer imaging and therapy. Furthermore, it demonstrates that a novel two-pronged treatment, combining immune-checkpoint inhibition and GNS-mediated photothermal nanotherapy, can not only eradicate primary treated tumors but also trigger immune responses to treat distant untreated tumors in a mouse animal model. Cancer has become a significant threat to human health with more than eight million deaths each year, and novel methods for cancer management to improve patients' overall survival are urgently needed. The developed multifunctional GNS nanoprobe with tip-enhanced plasmonics in the near-infrared region can be combined with (1) surface-enhanced Raman spectroscopy (SERS), (2) two-photon photoluminescence (TPL), (3) X-ray computed tomography (CT), (4) magnetic resonance imaging (MRI), (5) positron emission tomography (PET), and (6) photothermal therapy (PTT) for cancer imaging and treatment. The ability of the GNS nanoprobe to detect submillimeter intracranial brain tumors was demonstrated using PET scan - a superior non-invasive imaging modality - in a mouse animal model. In addition, delayed rechallenge with repeated cancer cell injection in cured mice did not lead to new tumor formation, indicating generation of a memorized immune response to cancer. The biocompatible gold nanostars with superior capabilities for cancer imaging and treatment have great potential for translational medicine applications.

Photodynamic Therapy: From Theory to Application brings attention to an exceptional treatment strategy, which until now has not achieved the recognition and breadth of applications it deserves. The authors, all experts and pioneers in their field, discuss the history and basic principles of PDT, as well as the fundamentals of the theory, methods, and instrumentation of clinical diagnosis and treatment of cancer. Non-oncological applications such as the use of PDT in control of parasites and noxious insects are also discussed. This book serves as a standard reference for researchers and students at all levels, clinical specialists interested in the topic and those in industry exploring new areas for development. A comprehensive exposition of both the theory and application of PDT, this book fills the gaps in the current literature by bringing together both basic understanding of the process of PDT and an expanded vision of its applications.

Where do you begin to look for a recent, authoritative article on the diag nosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals fre quently publish good in-depth reviews of cancer topics, and published sym posium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by di viding the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Timing, racing, combating, struggling and targeting are some actions through which cellular fate could be reflected and evaluated. Interaction between cell territory and environment occur during pre-embryonic, fetal development, and post-natal periods. What the researchers observe as the outcome of telomeres behavior is only the peak of an ice mountain within a stormy ocean. Cellular life depends on programmed behavior of telomeres, capable to surprise the cells. Telomeres provide an introduction to the history of our cells which govern the quality of life and status of health. Telomeres as the cooperative territory are capable of stabilizing the chromosomal territory. The status of telomeres reflects the key information, announcing the real age of individuals, and may be a valuable marker for prognosis and predicting cancer. Telomere territory is characterized with a multi-disciplinary manner. Therefore, this book is aimed to offer a wide range of chapters, hoping to be useful for diverse audiences, including hematologists-oncologists, radiotherapists, surgeons, cancer researchers, and all the sectors who affect the macro- and micro- environmental domains. Finally, telomeres are sensitive, cooperative, and trustable targets. It is worth to state that 'telomeres are messengers of NATURE', let's to know them as they are.

Understanding the role of hedgehog signaling in cancer is critically important for novel cancer therapeutics. The hedgehog pathway is a major pathway regulating cell differentiation, tissue polarity, stem cell maintenance and cell proliferation. It is known by now that activation of this pathway occurs in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia, gastrointestinal, lung, ovarian, breast and prostate cancers. This book provides insightful views suitable for graduate students, medical students, undergraduate students, basic and clinical scientists, cancer patients as well as the general public.

It was not too many years ago that the role of chemotherapy for head and neck cancer consisted of single-agent methotrexate for selected patients with recurrent disease. In the past decade, multiple new agents, high-dose chemotherapy, combinations, and intra-arterial approaches have been used for the patient with recurrent disease. Wheeler critically assesses the current status of these approaches. When oncologists began testing chemotherapy in the combined modality approach, trials consisted of induction chemotherapy and use of single agents as radiosensitizers. Although a great deal has been learned from these trials, benefit in terms of survival has been marginal. Even more promising may be the concomitant use of combination chemo therapy and radiation. Taylor describes the encouraging results as well as the potential. Induction chemotherapy may have a second important goal in addition to improving curability-it could be used for organ preservation. Dimery et al., present the background for this approach in the patient with laryngeal cancer as well as a description of their randomized trial for voice preservation. Head and neck squamous cancers are a heterogeneous group of diseases, and surgeons have long sought parameters that will help predict outcome."

Malnutrition and its related symptoms are both frequent and deleterious effects of cancer treatment. Despite the importance of targeted nutritional interventions in ameliorating these effects, however, publications providing up-to-date information on novel nutritional approaches and strategies are lacking. This book is intended to fill the void by describing and evaluating in detail the nutritional strategies that may be employed to alleviate a wide variety of cancer treatment effects. The guidance provided will help to improve the survival and quality of life of cancer patients, and has the potential to dramatically affect how evidence-based clinical practice is established and improved over the coming decade. The author is a distinguished expert in the field who has more than 25 years of experience in oncology nutrition and has been involved in establishing and implementing a Clinical Nutrition Oncology Program.